AttendMe Owl Logo
AttendMe
Evidence Evolution
NephrologyNephrology

How This Evidence Evolved

Contrast-Associated AKI

Rethinking the paradigm of contrast nephropathy prevention

13.5

Timeline

Tepel NAC 2000
2000
AMACING
2017
PRESERVE
2018
ACR
2020
ACR–NKF consensus on IV iodinated contrast in kidney disease
2020
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

Proof

Landmark RCTs and pivotal trials that established the evidence base

PRESERVE randomized 5177 high-risk angiography patients, with 4993 in its modified intention-to-treat analysis. At 90 days, death, dialysis or persistent creatinine increase ≥50% occurred in 4.4% with bicarbonate versus 4.7% with saline (P=0.62), and 4.6% with NAC versus 4.5% with placebo (P=0.88). The sponsor stopped the trial after a prespecified interim analysis. Neither intervention improved the composite outcome or contrast-associated AKI; the abstract does not specify the stopping reason.
Extension

Follow-up studies, subgroup analyses, and real-world validation

AMACING tested prophylactic IV saline in elective patients aged ≥18 years with eGFR 30–59 mL/min/1.73 m² undergoing iodinated contrast procedures. It randomized 660 patients and excluded eGFR <30 or previous dialysis. No prophylaxis was noninferior to IV hydration for contrast nephropathy: 2.6% versus 2.7% among patients with 2–6-day creatinine results. Hydration-associated complications occurred in 5.5% of hydrated patients. These results apply to the studied elective population, not all contrast exposures.
Guidelines

Integration into clinical practice guidelines and recommendations

ACR/NKF 2020 does not indicate IV-contrast prophylaxis for the general population with stable eGFR ≥30 mL/min/1.73 m². Saline is indicated for AKI or eGFR <30 without maintenance dialysis, considering heart-failure and hypervolemia risks; selected high-risk eGFR 30–44 may merit prophylaxis. NAC is not recommended for IV-contrast prophylaxis. Use the routine diagnostic IV dose.
ACR

IV hydration not routine for stable eGFR ≥30 with IV contrast; consider AKI/high-risk exceptions; no NAC; preserve diagnostic contrast dose.

Polish Society of Nephrology and Polish Medical Society of Radiology position statement

For routine repeated iodinated contrast: maintain 4 hours if eGFR >30; delay 48 hours if eGFR <30 mL/min/1.73 m². Emergency or life-threatening demand overrides these intervals.

Now

Current standard of care and ongoing research directions

PRESERVE found no benefit from NAC or bicarbonate over their comparators; AMACING questioned hydration in its elective eGFR 30–59 population. ACR/NKF distinguishes coincident contrast-associated AKI from injury caused by contrast and states that IV contrast risk has been overstated. For IV contrast, saline prophylaxis is indicated with AKI or eGFR <30 when not on maintenance dialysis, with attention to fluid-overload risk; selected high-risk patients at eGFR 30–44 may also receive it. Necessary imaging for a life-threatening diagnosis should not be withheld solely because of kidney function, and ad hoc contrast-dose reductions that impair diagnostic quality should be avoided.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Is N-acetylcysteine (NAC) effective for preventing contrast nephropathy?+
PRESERVE randomized 5177 high-risk angiography patients. The 90-day death/dialysis/persistent kidney-injury composite was 4.6% with NAC versus 4.5% with placebo (P=0.88). ACR/NKF does not recommend NAC for IV contrast prophylaxis.
Is IV hydration needed before contrast-enhanced imaging?+
AMACING randomized 660 elective patients with eGFR 30–59: no prophylaxis was noninferior to IV hydration for contrast nephropathy (2.6% versus 2.7%); 5.5% of hydrated patients had hydration complications. For IV contrast, ACR/NKF recommends saline prophylaxis with AKI or eGFR <30 when not on maintenance dialysis, considering fluid-overload risk. At eGFR 30–44, selected high-risk circumstances may justify prophylaxis. These IV-contrast recommendations do not automatically apply to intra-arterial exposure.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026